Regulus Therapeutics (RGLS) Sets New 52-Week High and Low at $0.61

Regulus Therapeutics Inc (NASDAQ:RGLS)’s share price hit a new 52-week high and low during trading on Tuesday . The company traded as low as $0.61 and last traded at $0.71, with a volume of 2242 shares. The stock had previously closed at $0.66.

A number of equities analysts recently commented on the stock. B. Riley assumed coverage on shares of Regulus Therapeutics in a research note on Wednesday, March 28th. They set a “neutral” rating and a $1.00 price target for the company. ValuEngine raised shares of Regulus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Zacks Investment Research cut shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 10th. Wedbush reaffirmed an “outperform” rating and set a $3.00 price target on shares of Regulus Therapeutics in a research note on Thursday, May 17th. Finally, BMO Capital Markets set a $1.00 price target on shares of Regulus Therapeutics and gave the stock a “hold” rating in a research note on Thursday, March 8th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $1.71.

The company has a market capitalization of $75.13 million, a P/E ratio of -0.72 and a beta of 1.68.



Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.15) EPS for the quarter, hitting analysts’ consensus estimates of ($0.15). Regulus Therapeutics had a negative net margin of 94,318.05% and a negative return on equity of 214.48%. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. sell-side analysts anticipate that Regulus Therapeutics Inc will post -0.61 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. A.R.T. Advisors LLC bought a new stake in Regulus Therapeutics during the 1st quarter valued at about $121,000. Renaissance Technologies LLC lifted its holdings in Regulus Therapeutics by 215.7% during the 4th quarter. Renaissance Technologies LLC now owns 137,589 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 94,000 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in Regulus Therapeutics by 18.2% during the 4th quarter. Victory Capital Management Inc. now owns 327,770 shares of the biopharmaceutical company’s stock valued at $341,000 after buying an additional 50,530 shares in the last quarter. Ascend Capital LLC bought a new stake in Regulus Therapeutics during the 4th quarter valued at about $1,053,000. Finally, BVF Inc. IL lifted its holdings in Regulus Therapeutics by 7.9% during the 4th quarter. BVF Inc. IL now owns 13,974,249 shares of the biopharmaceutical company’s stock valued at $14,533,000 after buying an additional 1,025,020 shares in the last quarter. Institutional investors own 50.93% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply